Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12,157 GBX | -0.27% | +1.30% | +14.94% |
11:19am | AstraZeneca's Tagrisso Reduces Lung Cancer Progression in Phase 3 Trial | MT |
10:35am | AstraZeneca: Tagrisso shows promise in lung cancer | CF |
ETFs positioned on AstraZeneca PLC
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
9.20% | 11 M€ | +0.83% | - | |
5.39% | 200 M€ | +17.15% | ||
5.17% | 17 M€ | +7.32% | - | |
4.89% | 693 M€ | +13.07% | ||
4.11% | 88 M€ | +10.37% | - | |
3.47% | 232 M€ | +13.68% | ||
2.74% | 4 M€ | -.--% | - | |
2.57% | 6 M€ | -.--% | ||
2.53% | 7 M€ | +9.96% | - | |
2.53% | 664 M€ | +9.77% | ||
1.54% | 29 M€ | +8.37% | - | |
1.51% | 2 M€ | -.--% | - | |
1.51% | 2 M€ | +9.19% | - | |
1.26% | 12 M€ | +15.09% | - | |
1.19% | 48 M€ | +9.42% | ||
1.16% | 10 M€ | -3.35% | - | |
0.97% | 7 M€ | +5.36% | - | |
0.89% | 32 M€ | +6.87% | - | |
0.86% | 276 M€ | +11.40% | - | |
0.70% | 264 M€ | -.--% | - | |
0.69% | 187 M€ | +9.30% | - | |
0.69% | 477 M€ | +12.83% | ||
0.57% | 205 M€ | -.--% | ||
0.54% | 284 M€ | -.--% | ||
0.51% | 23 M€ | -.--% | - | |
0.51% | 786 M€ | -.--% | ||
0.50% | 206 M€ | -.--% | ||
0.48% | 727 M€ | +8.84% | ||
0.43% | 283 M€ | +21.58% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.94% | 240B | |
+40.73% | 739B | |
+31.93% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+9.47% | 210B | |
-4.95% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- AZN Stock
- Funds and ETFs AstraZeneca PLC